Zydus Lifesciences shares rose as much as 2.05% to hit a 52‑week high of ₹1,228.60 on the National Stock Exchange on Monday, September 28, 2026. The rise followed the United States Food and Drug Administration’s conclusion of an on‑site inspection at the company’s New Jersey facility, which reported zero observations. The inspection covered the firm’s pharmacovigilance and post‑marketing surveillance system and ran from September 22 to September 25, 2026.

In the April‑June quarter of the 2026‑27 financial year, Zydus Lifesciences reported a 35.93% year‑on‑year decline in consolidated net profit, falling to ₹939.8 crore from ₹1,466.8 crore in the same period a year earlier. Revenue from operations increased 20.74% YoY to ₹8,123.1 crore, up from ₹6,728.6 crore in Q1 FY26. EBITDA declined 7.6% YoY to ₹1,929.4 crore, with the margin contracting 770 basis points to 24.1% from 31.8%.

At approximately 11:52 AM on September 28, the stock traded at ₹1,222.70, reflecting a 1.56% increase. Over the past week the scrip has risen more than 5%, and it has climbed 3% over the month. Year‑to‑date, the shares have surged 34%. The lowest point reached was ₹835.50 on April 2, 2026, while the current 52‑week high stands at ₹1,228.60.

Zydus Lifesciences had a market capitalisation of ₹1.22 lakh crore as of September 28, 2026, according to National Stock Exchange data. This figure is reported in the article but no further interpretation is provided. The market capitalisation is presented as a factual statement without attribution to any analysis or commentary.

A regulatory filing stated that the FDA conducted an on‑site inspection of the company’s pharmacovigilance and post‑marketing surveillance system at its New Jersey office. The inspection, conducted from September 22 to September 25, 2026, concluded with nil observations, indicating compliance with U.S. regulatory requirements.